Therapeutic compositions for the treatment of infectious diseases are disclosed. These compositions comprise xanthones and xanthone derivatives, such as 2,3,4,5,6-pentahydroxyxanthone. Also disclosed are methods for the treatment of infectious diseases using such compounds.

Treatment of peptic ulceration with xanthene derivatives

Xanthone analogs for the treatment of infectious diseases

Therapeutic compounds and compositions for the treatment of infectious diseases are disclosed. The compounds are xanthones and xanthone derivatives, such as 3,5-bis-e-(N,N-diethylamino)amyloxyxanthone. The described compositions include such compounds and a pharmaceutical carrier. These compositions also can include additional materials conventionally used to form therapeutic compositions. 3,5-bis-e-(N,N-diethylamino)amyloxyxanthone has an IC50 for Plasmodium falciparum of about 0.15 νM, and an IC50 for Leishmania mexicana of < <0.5 νM. These compositions are additionally useful for forming soluble complexes with heme and porphyrins.

Treatment of peptic ulceration with xanthene derivatives

Citations

Xanthone analogs for the treatment of infectious diseases

Xanthone analogs for treating infectious diseases and complexation of heme and porphyrins

Related Papers (5)

and Peptic Ulceration

New Drugs: Peptic ulceration

Experimental peptic ulceration.

Experimental peptic ulceration. II. The significance of peptic activity.

Serumpyridoxal inactive peptic ulceration